381 related articles for article (PubMed ID: 33519461)
1. Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats.
Zhang W; Liu J; Fu Y; Ji H; Fang Z; Zhou W; Fan H; Zhang Y; Liao Y; Yang T; Wang X; Yuan W; Chen X; Dong YF
Front Pharmacol; 2020; 11():600953. PubMed ID: 33519461
[TBL] [Abstract][Full Text] [Related]
2. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction.
Shi YJ; Yang CG; Qiao WB; Liu YC; Liu SY; Dong GJ
Eur J Pharmacol; 2023 Dec; 961():176170. PubMed ID: 37939991
[TBL] [Abstract][Full Text] [Related]
3. Protective Effects of Sacubitril/Valsartan on Cardiac Fibrosis and Function in Rats With Experimental Myocardial Infarction Involves Inhibition of Collagen Synthesis by Myocardial Fibroblasts Through Downregulating TGF-β1/Smads Pathway.
Wu M; Guo Y; Wu Y; Xu K; Lin L
Front Pharmacol; 2021; 12():696472. PubMed ID: 34135764
[No Abstract] [Full Text] [Related]
4. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
[TBL] [Abstract][Full Text] [Related]
5. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
Nordén ES; Bendiksen BA; Andresen H; Bergo KK; Espe EK; Hasic A; Hauge-Iversen IM; Veras I; Hussain RI; Sjaastad I; Christensen G; Cataliotti A
ESC Heart Fail; 2021 Apr; 8(2):918-927. PubMed ID: 33497525
[TBL] [Abstract][Full Text] [Related]
6. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
Myakala K; Jones BA; Wang XX; Levi M
Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
[TBL] [Abstract][Full Text] [Related]
7. Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease.
Croteau D; Qin F; Chambers JM; Kallick E; Luptak I; Panagia M; Pimentel DR; Siwik DA; Colucci WS
JACC Basic Transl Sci; 2020 Sep; 5(9):916-927. PubMed ID: 33015414
[TBL] [Abstract][Full Text] [Related]
8. Early Passive Leg Movement Prevents Against the Development of Heart Failure With Preserved Ejection Fraction in Rats.
Liu J; Ji XX; Fu Y; Zhang WC; Ji HF; Liu JW; Cheng XS; Dong YF
Front Cardiovasc Med; 2021; 8():655009. PubMed ID: 33969019
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study.
Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
Am J Health Syst Pharm; 2024 Mar; ():. PubMed ID: 38427969
[TBL] [Abstract][Full Text] [Related]
10. Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect.
Tashiro K; Kuwano T; Ideishi A; Morita H; Idemoto Y; Goto M; Suematsu Y; Miura SI
Cardiol Res; 2020 Dec; 11(6):376-385. PubMed ID: 33224383
[TBL] [Abstract][Full Text] [Related]
11. Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis.
Fu S; Xu Z; Lin B; Chen J; Huang Q; Xu Y; Xu A; Chen Y; Tang Y
Front Med (Lausanne); 2021; 8():657067. PubMed ID: 34235161
[No Abstract] [Full Text] [Related]
12. Strain-selective efficacy of sacubitril/valsartan on carotid fibrosis in response to injury in two inbred mouse strains.
Korshunov VA; Quinn B; Faiyaz A; Ahmed R; Sowden MP; Doyley MM; Berk BC
Br J Pharmacol; 2019 Aug; 176(15):2795-2807. PubMed ID: 31077344
[TBL] [Abstract][Full Text] [Related]
13. Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
Nishio H; Ishii A; Yamada H; Mori KP; Kato Y; Ohno S; Handa T; Sugioka S; Ishimura T; Ikushima A; Inoue Y; Minamino N; Mukoyama M; Yanagita M; Yokoi H
Nephrol Dial Transplant; 2023 Oct; 38(11):2517-2527. PubMed ID: 37202215
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data.
Cuthbert JJ; Pellicori P; Clark AL
Ther Clin Risk Manag; 2020; 16():715-726. PubMed ID: 32848403
[TBL] [Abstract][Full Text] [Related]
15. Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China.
Wu Y; Tian S; Rong P; Zhang F; Chen Y; Guo X; Zhou B
Front Pharmacol; 2020; 11():1101. PubMed ID: 32792946
[TBL] [Abstract][Full Text] [Related]
16. A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation.
Suzuki J; Kaji K; Nishimura N; Kubo T; Tomooka F; Shibamoto A; Iwai S; Tsuji Y; Fujinaga Y; Kitagawa K; Namisaki T; Akahane T; Yoshiji H
Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238965
[TBL] [Abstract][Full Text] [Related]
17. Sacubitril/valsartan attenuates myocardial ischemia/reperfusion injury via inhibition of the GSK3β/NF-κB pathway in cardiomyocytes.
Xiao F; Wang L; Liu M; Chen M; He H; Jia Z; Zhang L; Yang Y; Hu Q; Hong M; Zhang H
Arch Biochem Biophys; 2022 Nov; 730():109415. PubMed ID: 36179911
[TBL] [Abstract][Full Text] [Related]
18. Sacubitril/valsartan ameliorates tubulointerstitial fibrosis by restoring mitochondrial homeostasis in diabetic kidney disease.
Zhang XJ; Liu CC; Li ZL; Ding L; Zhou Y; Zhang DJ; Zhang Y; Hou ST; Ma RX
Diabetol Metab Syndr; 2024 Feb; 16(1):40. PubMed ID: 38341600
[TBL] [Abstract][Full Text] [Related]
19. Combination of sacubitril/valsartan and blockade of the PI3K pathway enhanced kidney protection in a mouse model of cardiorenal syndrome.
Tsukamoto S; Wakui H; Uehara T; Shiba Y; Azushima K; Abe E; Tanaka S; Taguchi S; Hirota K; Urate S; Suzuki T; Yamada T; Kinguchi S; Yamashita A; Tamura K
Eur Heart J Open; 2023 Nov; 3(6):oead098. PubMed ID: 37941728
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
